search button
Open Access

Suppression of dopamine receptor 2 inhibits the formation of human prostate cancer PC‑3‑derived cancer stem cell‑like cells through AMPK inhibition

  • Authors:
    • Juyeon Park
    • Hee Jun Jang
    • Won Ki Jung
    • Da Yeon Kang
    • You Li Gong
    • Hee-Jeong Kim
    • Jong Soon Kang
    • Jeong Wook Yang
    • Youngjoo Byun
    • Song-Kyu Park

  • View Affiliations

  • Published online on: January 14, 2025     https://doi.org/10.3892/ol.2025.14888
  • Article Number: 142

  • Copyright: © Park et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Cancer stem cells (CSCs) contribute to the resistance of intractable prostate cancer, and dopamine receptor (DR)D2 antagonists exhibit anticancer activity against prostate cancer and CSCs. Human prostate cancer PC‑3 cells were used to generate CSC‑like cells, serving as a surrogate system to identify the specific DR subtype the inhibition of which significantly affects prostate‑derived CSCs. Additionally, the present study aimed to determine the downstream signaling molecules of this DR subtype that exert more profound effects compared with other DR subtypes. The inhibitory effects of specific antagonists or small interfering (si)RNAs on DR subtypes were compared by analyzing morphological changes of cells, expression patterns of pluripotency markers, cell growth inhibitory activities and in vitro cell invasion. L‑741,626, a specific DRD2 antagonist, induced morphological changes in PC‑3‑derived CSC‑like cells, suppressed the expression of Oct4 (a pluripotency marker), and inhibited the growth of cells and tumors. The proliferation of heterozygous null PC‑3 cells, generated using the CRISPR/Cas9 method, was slow, and their sphere‑forming ability was substantially reduced, indicating a diminished capacity to produce CSCs. In addition, the phosphorylation of AMPK was suppressed by DRD2 siRNA and the heterozygous knockout of DRD2 in PC‑3 cells, indicating that AMPK may be a putative downstream signaling molecule involved in the production and maintenance of PC‑3‑derived CSC‑like cells. Specific inhibition or suppression of DRD2 caused PC‑3‑derived CSC‑like cells to lose their properties and inhibited the formation of PC‑3‑derived CSC‑like cells, followed by inhibition of the phosphorylation of AMPK, which is considered a putative downstream signaling molecule of DRD2. Further understanding of the mechanisms by which DRD2 regulates AMPK and the effects of AMPK inhibition on the properties of PC‑3‑derived CSC‑like cells may provide valuable insights into the identification of molecular targets for treating intractable prostate cancer wherein AMPK is constitutively activated.
View Figures
View References

Related Articles

Journal Cover

March-2025
Volume 29 Issue 3

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

  • Journal Metrics
  • Impact Factor: 2.5
  • Ranked Oncology
    (total number of cites)
  • CiteScore: 5.7
  • CiteScore Rank: Q2: #139/404 Oncology
  • Source Normalized Impact per Paper (SNIP): 0.574
  • SCImago Journal Rank (SJR): 0.644
International Symposium on Molecular Medicine Conference Banner
The Cancer Story
World Congress on Advances in Oncology and International Symposium on Molecular Medicine Conference Banner
World Academy Of Sciences Banner
Heyday Road Banner

0

Copy and paste a formatted citation
x
Spandidos Publications style
Park J, Jang HJ, Jung WK, Kang DY, Gong YL, Kim H, Kang JS, Yang JW, Byun Y, Park S, Park S, et al: Suppression of dopamine receptor 2 inhibits the formation of human prostate cancer PC‑3‑derived cancer stem cell‑like cells through AMPK inhibition. Oncol Lett 29: 142, 2025.
APA
Park, J., Jang, H.J., Jung, W.K., Kang, D.Y., Gong, Y.L., Kim, H. ... Park, S. (2025). Suppression of dopamine receptor 2 inhibits the formation of human prostate cancer PC‑3‑derived cancer stem cell‑like cells through AMPK inhibition. Oncology Letters, 29, 142. https://doi.org/10.3892/ol.2025.14888
MLA
Park, J., Jang, H. J., Jung, W. K., Kang, D. Y., Gong, Y. L., Kim, H., Kang, J. S., Yang, J. W., Byun, Y., Park, S."Suppression of dopamine receptor 2 inhibits the formation of human prostate cancer PC‑3‑derived cancer stem cell‑like cells through AMPK inhibition". Oncology Letters 29.3 (2025): 142.
Chicago
Park, J., Jang, H. J., Jung, W. K., Kang, D. Y., Gong, Y. L., Kim, H., Kang, J. S., Yang, J. W., Byun, Y., Park, S."Suppression of dopamine receptor 2 inhibits the formation of human prostate cancer PC‑3‑derived cancer stem cell‑like cells through AMPK inhibition". Oncology Letters 29, no. 3 (2025): 142. https://doi.org/10.3892/ol.2025.14888